We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Fluxion Biosciences and Swift Biosciences Announce New Workflow
Product News

Fluxion Biosciences and Swift Biosciences Announce New Workflow

Fluxion Biosciences and Swift Biosciences Announce New Workflow
Product News

Fluxion Biosciences and Swift Biosciences Announce New Workflow

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Fluxion Biosciences and Swift Biosciences Announce New Workflow"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In advance of the 2015 American Society of Clinical Oncology Annual meeting, Fluxion Biosciences, Inc. and Swift Biosciences, Inc. have announced a new workflow for oncology clinical research designed to detect somatic mutations from a routine blood draw.

The jointly-developed workflow utilizes Fluxion’s IsoFlux™ System for circulating tumor cell (CTC) enrichment and Swift’s Accel-Amplicon™ technology for high sensitivity variant detection using low starting inputs.

Liquid biopsies represent a major breakthrough in the ability to detect molecular changes in tumor progression without the need for a tissue biopsy. They offer the potential to characterize cancer in real time using only a routine blood draw, enabling targeted therapies to be used simultaneously monitoring for response and resistance.

Until recently, this approach has been limited by the available amount of tumor DNA that can be recovered from peripheral blood samples. The IsoFlux System enriches rare tumor cells circulating in the blood using a combination of epithelial and mesenchymal markers, and delivers them at high purity for molecular analysis. Swift’s Accel-Amplicon 56G Oncology Panel provides sensitive mutation detection across 56 cancer-related genes using very low starting DNA inputs from the IsoFlux System, making this combination of technologies especially appropriate for liquid biopsy samples.

“We’re pleased to be working with Swift on this application for translational oncology research,” said Michael Schwartz, VP Marketing at Fluxion. “We expect the combination of blood-based tumor DNA enrichment and broad tumor gene coverage to be put to good use by the types of institutions that are pursuing diagnostic strategies based on liquid biopsies.”

“This workflow is a wonderful example of how innovators can collaborate to produce advanced tools for oncology research,” noted David Olson, CEO at Swift Biosciences. “Fluxion's CTC enrichment is a great pairing with our 56G Oncology Panel, and we are pleased that our respective technologies can be used together to shine new light on cancer biology.”

The combined workflow begins with a standard blood draw and proceeds to CTC enrichment using epithelial and mesenchymal antibodies. The captured CTCs undergo DNA extraction and purification without the need for whole genome amplification. The genomic DNA then goes through target enrichment using the 56G Oncology Panel and library preparation for Illumina sequencers.

The resulting data utilizes a custom bioinformatics pipeline designed to identify low frequency variants from liquid biopsy samples. The complete workflow is described in an application note and the products involved are available from Fluxion and Swift.